Enhanced efficacy of rFVIII-PEG-Lip after tail vein transection in HemA mice. (A) HemA mice received tail vein injections of 50 μL rFVIII formulation buffer (excipient) or rFVIII at a dose of 4, 13, 40, 100, and 200 IU/kg. Twenty-four hours later, 1 of the lateral tail veins was transected, and the percentage of mice that survived the injury was monitored hourly for the first 11 hours and then at 24 hours. (B) Plot of the rFVIII dose response in percentage of survival after tail vein transaction as shown in panel A. (C) Comparison of the survival curves of HemA mice treated with 13 IU/kg rFVIII formulated in buffer, or PEG-Liposome, or sequential injection of PEG-Liposome followed by rFVIII, or 50 μL PEG-Liposome (excipient). Two-tailed P values were determined by the log-rank test on the respective survival curves.